For years, Medicare has been legally prohibited from covering weight loss drugs like Ozempic when prescribed solely for weight management, leaving many beneficiaries facing list prices of $1,000 or more per month for GLP-1 medications. A new federal program is changing that, at least temporarily. Starting July 1, 2026, the Medicare GLP-1 Bridge allows certain beneficiaries to get select GLP-1 weight loss medications for a flat $50 per month.
Here is what the program covers, who may qualify, how to apply, and the fine print to understand before counting on this coverage long term.
What Is the Medicare GLP-1 Bridge?
The GLP-1 Bridge is a new program from the Centers for Medicare & Medicaid Services (CMS) running from July 1, 2026 through December 31, 2027. During that window, eligible beneficiaries can fill prescriptions for certain GLP-1 medications used for weight management and pay a flat $50 copay per month at the pharmacy.
What makes the Bridge unusual is that it operates outside the normal Medicare Part D benefit and payment flow. Rather than routing claims through each beneficiary's individual drug plan, CMS uses a single central processor to handle prior authorizations and pharmacy claims nationwide. Your Part D plan's formulary, deductible, and coverage phases do not apply to Bridge prescriptions.
The name reflects the program's purpose: it is a temporary arrangement with a firm end date, intended to provide access while the federal government works out a longer-term approach. Coverage beyond that date is not assured.
Which Drugs Are Included
The Bridge covers a limited list of GLP-1 products when prescribed for weight management:
- Wegovy (semaglutide) — both the injection and the newer tablet form
- Zepbound (tirzepatide) — KwikPen only. The single-dose vials and single-dose pens of Zepbound are excluded from the program
- Foundayo
These drugs cost the program approximately $245 per month — a steep discount from typical list prices — and the beneficiary pays the flat $50 copay, with the program covering the difference.
Other GLP-1 medications, such as Ozempic and Mounjaro, are not part of the Bridge because they are approved for diabetes rather than weight management; they remain available through regular Part D coverage for covered conditions.
Who May Qualify
Eligibility has two parts: clinical criteria and coverage requirements. You generally need to meet both.
Clinical criteria. You may qualify if you meet any one of the following:
- A body mass index (BMI) of 35 or greater, or
- A BMI of 30 or greater plus at least one of these conditions: heart failure, uncontrolled hypertension, or chronic kidney disease, or
- A BMI of 27 or greater plus at least one of these conditions: pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease
Coverage requirements. You must be enrolled in 2026 in either:
- A standalone Part D prescription drug plan (PDP), or
- A Medicare Advantage coordinated care plan that includes drug coverage (MA-PD)
Beneficiaries in Special Needs Plans (SNPs), employer or union group waiver plans, and the Limited Income Newly Eligible Transition (LI NET) program are also eligible. However, you are not eligible if your only drug coverage comes through a Private Fee-for-Service (PFFS) plan, a cost contract plan, or PACE.
Meeting the BMI thresholds does not automatically enroll you — your provider must submit clinical documentation, and not everyone who applies will be approved.
If You Have Diabetes or Sleep Apnea, Use Part D Instead
The Bridge is designed for beneficiaries whose only qualifying indication is weight management — the use Part D has historically been barred from covering. Several GLP-1 indications are already coverable under regular Part D:
- Type 2 diabetes
- Moderate-to-severe obstructive sleep apnea
- MASH (metabolic dysfunction-associated steatohepatitis, a serious liver condition)
If you have one of these diagnoses, your GLP-1 prescription generally goes through your Part D plan, and you are ineligible for the Bridge. This can matter for your costs: Part D claims count toward your annual out-of-pocket cap, and beneficiaries with Extra Help receive reduced cost-sharing through Part D. Check your plan's formulary and cost-sharing to see which path applies to you.
How to Apply
You do not apply for the Bridge on your own. The process runs through your health care provider:
- Talk to your doctor about whether a covered GLP-1 medication is clinically appropriate for you and whether you meet the program's criteria.
- Your provider submits a prior authorization request directly to Humana, the CMS-contracted central processor for the program — the same processor for all beneficiaries nationwide, regardless of which plan you have.
- Once approved, you pay the flat $50 copay at the pharmacy for each monthly fill.
You can check program details and eligibility at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE (1-800-633-4227). TTY users can call 1-877-486-2048.
If you are weighing GLP-1 medication as part of a broader weight management plan, it may also be worth reviewing what Medicare covers for weight loss surgery, since that benefit follows different rules.
Important Fine Print
Because the Bridge sits outside the normal Part D benefit, several familiar Part D protections do not apply:
- The $50 copay does not count toward your Part D out-of-pocket cap. In 2026, the Part D out-of-pocket cap is $2,100, and spending that counts toward it is tracked as "TrOOP" (true out-of-pocket costs). Bridge copays are excluded from TrOOP, so they will not move you closer to the cap.
- Extra Help does not reduce the $50. Beneficiaries with the Low-Income Subsidy pay the same flat $50 copay as everyone else in the program.
- The Part D deductible does not apply. You pay $50 from your first fill — the program ignores your plan's deductible (up to $615 in 2026).
In short, the Bridge is self-contained: a predictable $50 per month, with no interaction with the cost protections built into regular Part D.
What Happens After 2027
The Bridge was originally planned as a six-month program, but CMS extended it to 18 months — through December 31, 2027 — after not enough insurers signed on to the planned successor arrangement. That successor, a payment model known as BALANCE, has been indefinitely postponed.
That leaves a significant open question: coverage after December 2027 is currently undecided. If you start a GLP-1 through the Bridge, understand that coverage beyond the end date is not assured, even though these medications are generally intended for ongoing use.
The stakes are substantial: a KFF analysis estimates roughly 3.8 million Medicare beneficiaries could be eligible based on the clinical criteria. Whether permanent coverage is established before the Bridge expires will shape access for years to come.
How to Get Help and Learn More
Deciding whether the Bridge fits your situation involves both medical and coverage questions. These resources may help:
- Your doctor or health care provider — Only a provider can determine whether you meet the clinical criteria and submit the prior authorization to Humana on your behalf.
- Medicare.gov — Visit Medicare.gov and Medicare.gov/glp1bridge for official details, covered drugs, and eligibility rules.
- 1-800-MEDICARE (1-800-633-4227) — Medicare's official helpline can answer questions about the Bridge and your drug coverage. TTY users can call 1-877-486-2048.
- State Health Insurance Assistance Program (SHIP) — SHIP offers free, unbiased counseling from trained volunteers who can help you compare the Bridge against your Part D options. Find your local program at shiphelp.org or by calling 1-800-MEDICARE.
- CMS.gov — For policy-level details about the program and the BALANCE model, visit CMS.gov.
Summary and Next Steps
The Medicare GLP-1 Bridge opens a door long closed to Medicare beneficiaries — but it is a temporary one. Key points to remember:
- The Bridge runs from July 1, 2026 through December 31, 2027 and offers eligible beneficiaries certain GLP-1 weight loss drugs for a flat $50 per month
- Covered drugs are Wegovy (injection and tablets), Zepbound KwikPen (vials and single-dose pens excluded), and Foundayo
- You may qualify with a BMI of 35+, a BMI of 30+ with certain heart or kidney conditions, or a BMI of 27+ with pre-diabetes or certain cardiovascular history — plus enrollment in an eligible Part D or Medicare Advantage plan
- If you have type 2 diabetes, moderate-to-severe sleep apnea, or MASH, your GLP-1 coverage runs through regular Part D, not the Bridge
- Your provider applies for you by submitting a prior authorization to Humana, the program's central processor
- The $50 does not count toward the $2,100 out-of-pocket cap, and Extra Help does not lower it
- Coverage after December 2027 is undecided — the planned successor model has been postponed
If you think you may qualify, start with a conversation with your doctor about whether a covered GLP-1 is right for you. Then contact your local SHIP counselor or call 1-800-MEDICARE to confirm your plan type is eligible before counting on the $50 rate.
